Molecules of the Month

January 2023

The first, approved non-covalent BTKi, a next-generation oral SERD, a bioactive metabolite of a GHSR1a inverse agonist with the same therapeutic effect but different MOA to its parent are just some of the examples for this month's MOTM. Learn more about the molecules by navigating to the full reviews on the right which cover: why the molecules matter, how they were discovered, the key steps behind optimization, how they work, why the targets were chosen, any interesting toxicology and clinical data, and more. Sign up for our free weekly newsletter here to get more content like this straight to your inbox. Not a member? Get a free trial to check out substructure search and more features.


MOTY Nominees

Molecule of the Year

Nominate a molecule
Saw an interesting case study recently? Share it with the community!
Become a reviewer
Interested in helping assess new topics and providing scientific input? Get connected!

Join the Drug Hunter Mailing List

to get free content and resources weekly. Trusted by >8,000 drug hunters worldwide. Unsubscribe anytime.